Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).

Mol Clin Oncol

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Published: September 2014

The knowledge of tumor biology and the biomechanical properties of the urothelium have led to significant advances in the development of intravesical therapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Targeted therapy improves the efficacy and decreases the side effects of antineoplastic agents. Nanoparticles that target antitumor agents to the urothelial cells have allowed for improved delivery of these agents to tumor cells. Gene therapy is another strategy that has allowed for a targeted induction of an antitumor response. Finally, engineering of the bacillus Calmette-Guérin (BCG) vaccine aimed to minimize the potential side effects associated with this treatment. These novel approaches hold promise for decreasing the rate of progression and recurrence of NMIBC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106746PMC
http://dx.doi.org/10.3892/mco.2014.314DOI Listing

Publication Analysis

Top Keywords

intravesical therapy
8
therapy treatment
8
treatment non-muscle
8
non-muscle invasive
8
invasive bladder
8
bladder cancer
8
side effects
8
advances intravesical
4
therapy
4
cancer review
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!